Crohn's Disease Clinical Trials
Here are the 6 most popular medical studies for crohn's disease
Dietary Intervention
Diet-CD for Crohn's Disease During Pregnancy
This trial will test whether a dietary intervention during pregnancy can improve the gut microbiota composition in both pregnant Crohn's disease patients and their babies, and whether this can lead to decreased risk of maternal disease relapse postpartum and decreased functional gastrointestinal disorders and gut inflammation in their babies.
Popular filter options for crohn's disease trials
Inflammatory Bowel Disease Clinical Trials
View 30 Inflammatory Bowel Disease medical studies.
Probiotic
Probiotics for Inflammatory Bowel Disease
This trial is a single-site, randomized, double-blind, placebo-controlled trial of a probiotic supplement. The study will last 12 weeks and will compare the effects of the probiotic on the gut microbiome, metabolomic profile, and fatigue symptoms in patients with quiescent IBD.
2'-FL Supplement for Inflammatory Bowel Disease
This trial is testing whether a supplement called 2'-FL is safe and effective in treating inflammatory bowel diseases like Crohn's Disease and ulcerative colitis. 1, 5, or 10 gm of 2'-FL will be given daily compared to a placebo to see if it increases the abundance of good bacteria and butyrate in the gut.
IBD Clinical Trials
View 30 IBD medical studies.
Probiotic
Probiotics for Inflammatory Bowel Disease
This trial is a single-site, randomized, double-blind, placebo-controlled trial of a probiotic supplement. The study will last 12 weeks and will compare the effects of the probiotic on the gut microbiome, metabolomic profile, and fatigue symptoms in patients with quiescent IBD.
2'-FL Supplement for Inflammatory Bowel Disease
This trial is testing whether a supplement called 2'-FL is safe and effective in treating inflammatory bowel diseases like Crohn's Disease and ulcerative colitis. 1, 5, or 10 gm of 2'-FL will be given daily compared to a placebo to see if it increases the abundance of good bacteria and butyrate in the gut.
View More Crohn's Disease Trials
See another 72 medical studies focused on crohn's disease.
Frequently Asked Questions
Introduction to crohn's disease
What are the top hospitals conducting crohn's disease research?
When it comes to advancing the treatment options for individuals with Crohn's disease, several hospitals are leading the charge. Boston Children's Hospital in Boston is at the forefront of research and innovation, currently conducting eight active clinical trials for this condition. Since their first recorded trial in 2015, they have completed a total of 15 trials dedicated to understanding and improving outcomes for those living with Crohn's disease.
Moving south to Clearwater, Florida, Gastro Florida is also making significant strides in Crohn's disease research. With seven ongoing trials and a history of 14 previous studies since their initial trial in 2017, this hospital is actively contributing to the body of knowledge surrounding this chronic inflammatory bowel disorder.
In Nashville, Tennessee, Vanderbilt University Medical Center has established itself as a prominent institution when it comes to studying Crohn's disease. Currently engaged in seven active clinical trials and having conducted an impressive total of 46 trials since their inaugural investigation in 2004.
Indiana University located in Indianapolis plays its part too; engaging six active crohn’s diseases investigations while having expertise stemming from fifteentrials through starting early work on tackling such cases back towards2007
Yale University based out New Haven might be smaller-scale but still holds valuable contributions by carrying out six contemporary tests whilst maintaining record building nineinvestigations only dating back until 2014.
These hospitals represent beacons of hope for individuals affected by Crohn's disease worldwide. By investing significant resources into clinical trials focused on enhancing our understanding and treatment options for this complex condition these institutions play crucial roles aidingin shaping better future outlooks not just locally but globally
Which are the best cities for crohn's disease clinical trials?
When it comes to crohn's disease clinical trials, several cities emerge as top contenders for cutting-edge research. New york leads the way with 49 active trials focusing on promising treatments like Ozanimod, Risankizumab SC, and PF-06651600. Miami follows closely behind with 37 ongoing studies investigating potential breakthroughs such as Ozanimod, Mirikizumab, and Etrasimod. Atlanta also stands out with 33 active trials exploring treatment options like Ozanimod, Mirikizumab, and Ustekinumab. Additionally, Chicago and Orlando showcase their commitment to advancing crohn's disease care through their respective 27 and 26 active trials that delve into promising interventions including Ozanimod, Upadacitinib, Mirikizumab, Guselkumab Dose 3. These cities offer individuals living with crohn's disease opportunities to participate in groundbreaking clinical trials that hold promise for improved management of the condition.
Which are the top treatments for crohn's disease being explored in clinical trials?
Crohn's disease, a challenging condition to manage, has seen promising advancements in recent clinical trials. Leading the pack is ozanimod, currently being explored in five active trials dedicated to this chronic inflammatory disorder since its introduction in 2018. Close behind is ustekinumab with three ongoing studies and an impressive track record of 27 all-time crohn's disease trials since 2013. Also vying for attention is mirikizumab which shares similar stats as ustekinumab—three active trials and five all-time crohn's disease trials starting from 2016. Lastly, resistant starch joins the race with two active and two all-time crohn's disease trials listed from 2020 onwards. These cutting-edge treatments offer hope for improved management and quality of life for patients grappling with Crohn’s disease.
What are the most recent clinical trials for crohn's disease?
Recent clinical trials have brought new hope to individuals living with Crohn's disease, a challenging condition that affects the digestive system. One groundbreaking study focuses on guselkumab IV, an open-label induction phase treatment for Crohn's disease that has entered Phase 3 of testing, becoming available for participants from September 21, 2023. Another promising trial involves ozanimod and its potential application in managing Crohn's disease; it has reached Phases 2 and 3 as of August 22, 2023. Additionally, there is ongoing research into the effectiveness of anti-IL12/23 or anti-IL23 medications in treating Crohn's disease during its Phase 4 stage since August1st, 2023. These advancements bring optimism to patients seeking better outcomes through cutting-edge therapies tailored specifically for their needs.
What crohn's disease clinical trials were recently completed?
Recently completed clinical trials for Crohn's disease have shown promising advancements in the field. Stanford University successfully concluded a trial investigating the use of Vitamin d in July 2021, while UCB Biopharma SRL wrapped up their study on certolizumab pegol pharmacokinetics in June 2020. AbbVie also reached a significant milestone with their Risankizumab trial in May 2020. These trials, along with others conducted by Reistone Biopharma Company Limited, Genentech Inc., Janssen-Cilag Ltd., and other reputable sponsors, contribute to our understanding of potential treatments for Crohn's disease and offer hope to patients navigating this challenging condition.